# Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

> **NCT01743859** · PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 37 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Lenalidomide
- **OTHER:** Off Therapy

## Key facts

- **NCT ID:** NCT01743859
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-06
- **Primary completion:** 2016-04-27
- **Final completion:** 2016-08-03
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01743859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01743859, "Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01743859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*